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Chagas disease is a neglected parasitic illness affecting approximately 8 million people, predominantly in Latin America. Ben-
znidazole is the drug of choice for treatment, although its availability has been limited. A paucity of knowledge of the pharmaco-
kinetic properties of this drug has contributed to its limited availability in several jurisdictions. The objective of this study was to
conduct a systematic literature review and a Bayesian meta-analysis of pharmacokinetic studies to improve estimates of the basic
pharmacokinetic properties of benznidazole. A systematic search of the Embase, Medline, LILACS, and SciELO (Scientific Elec-
tronic Library Online) databases was conducted. Eligible studies reported patient-level data from single-100-mg-dose pharmaco-
kinetic evaluations of benznidazole in adults or otherwise provided data relevant to the estimation of pharmacokinetic parame-
ters which could be derived from such studies. A Bayesian hierarchical model was used for analysis. Secondary data (i.e., data
from studies that did not include patient-level, single-100-mg-dose data) were used for the generation of empirical priors for the
Bayesian analysis. The systematic search identified nine studies for inclusion. Nine pharmacokinetic parameters were estimated,
including the area under the concentration-time curve (AUC), the maximum concentration of drug in plasma (Cmax), the time to
Cmax, the elimination rate constant (kel), the absorption rate constant (Ka), the absorption and elimination half-lives, the appar-
ent oral clearance, and the apparent oral volume of distribution. The results showed consistency across studies. AUC and Cmax
were 51.31 mg · h/liter (95% credible interval [CrI], 45.01, 60.28 mg · h/liter) and 2.19 mg/liter (95% CrI, 2.06, 2.33 mg/liter), re-
spectively.Ka and kel were 1.16 h
1 (95% CrI, 0.59, 1.76 h1) and 0.052 h1 (95% CrI, 0.045, 0.059 h1), respectively, with the
corresponding absorption and elimination half-lives being 0.60 h (95% CrI, 0.38, 1.11 h) and 13.27 h (95% CrI, 11.79, 15.42 h),
respectively. The oral clearance and volume of distribution were 2.04 liters/h (95% CrI, 1.77, 2.32 liters/h) and 39.19 liters (95%
CrI, 36.58, 42.17 liters), respectively. A Bayesian meta-analysis was used to improve the estimates of the standard pharmacoki-
netic parameters of benznidazole. These data can inform clinicians and policy makers as access to this drug increases.
Chagas disease, also known as American trypanosomiasis, is aparasitic illness affecting approximately 8 million people
worldwide, with most cases being found in continental Latin
America (1), although it is increasingly recognized in developed
countries outside the traditional area of endemicity for vectorial
transmission, due to migration and vertical transmission to the
offspring of infected migrant mothers. Chagas disease is primarily
transmitted by exposure to the feces of infected triatomine bugs,
also known as “kissing bugs.” Infection can also occur through
means such as mother-to-child transmission, transfusion from
the blood of an infected individual, or organ transplantation from
an infected donor or can be foodborne. During the acute phase of
infection, patients tend to have a variety of symptoms ranging
from skin lesions and a swelling eyelid to flu-like symptoms, in-
cluding fever, headache, and muscle pain. Chronic Chagas disease
can lead to more critical injuries, with up to 30% of patients suf-
fering from cardiac disorders and up to 10% suffering from diges-
tive or neurological symptoms. As injury to the cardiovascular
system progresses, Chagas disease can lead to sudden death or
heart failure, caused by progressive destruction of the heart mus-
cle and its nervous system (2, 3).
Two drugs are currently used for the treatment of Chagas dis-
ease and have been shown to be very effective if they are used early
in the disease process. Both benznidazole, a nitroimidazole deriv-
ative, and nifurtimox, a nitrofuran, act on the parasite through the
formation of free radicals and/or electrophilic metabolites. Of
these two drugs, benznidazole is the preferred agent because of a
lower incidence of side effects (4–6). Recent evidence suggests that
benznidazole is also effective in the chronic phase of Chagas dis-
ease, although in a randomized clinical trial, treatment signifi-
cantly reduced the rate of detection of circulating parasites but did
not reduce clinical progression to cardiac disorders (7, 8). The
availability of both treatments has been limited, however, and
Doctors Without Borders/Médecins sans Frontières reported ma-
jor shortages of benznidazole in 2011, as the primary manufac-
turer, Hoffmann-La Roche, suspended production and trans-
ferred the technology and license to Lafepe Labs in Brazil in 2003
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(9). Bayer has since renewed production of nifurtimox, while Elea
Laboratory in Argentina has been producing benznidazole since
2012. In 2014, Elea started a joint project with Liconsa labs
(Chemo Group) in Spain, which is currently under FDA revision
process for approval. Recently, Lafepe Labs in Brazil announced
that the Brazilian regulatory agency has approved the use of its
benznidazole product. In 2011, a 12.5-mg pediatric dosage form
(manufactured by Lafepe Labs and DNDi) was registered by the
Brazilian Health Surveillance Agency to further improve the treat-
ment of pediatric Chagas disease.
With the inconsistent availability of benznidazole throughout
several countries, it is of critical importance that basic pharmaco-
kinetic data be available to both clinicians and policy makers to
ensure evidence-informed decision making with regard to the
drug approval process. Thus, there is a requirement for a meta-
analysis of studies of the pharmacokinetics (PK) of benznidazole
with a special focus on the type of population studied (i.e., the type
of population according to age, ethnic background, dose, and reg-
imen).
The purpose of this study was to conduct a meta-analysis of the
pharmacokinetic studies of benznidazole that have been con-
ducted in an effort to improve estimates of the basic pharmacoki-
netic properties of benznidazole.
MATERIALS AND METHODS
Systematic literature search. A comprehensive search of the literature
was conducted using the Embase and Medline databases and the Latin
American databases SciELO (Scientific Electronic Library Online) and
LILACS. The Embase and Medline literature search strategies were con-
ducted using the OVID platform. The search was conducted on 4 May
2016, and the search strategy is provided in appendix A in the supplemen-
tal material. The scope of the systematic literature review can be broken
down into four components: population, interventions, outcomes, and
study design (Table 1).
Study selection anddata extraction.A study investigator evaluated all
abstracts and proceedings that were identified through the literature
search to be potentially relevant for the research question. Those consid-
ered potentially relevant were evaluated in full (i.e., the full text publica-
tion was acquired) to determine final eligibility status. For all eligible
studies, data on study characteristics, patient characteristics, and out-
comes were extracted in duplicate by two investigators. Any discrepancies
observed between the data extracted by the two data extractors were re-
solved through discussion, and when discrepancies could not be resolved,
a third reviewer was consulted. Where measures were available only in
graphical format, the software DigitizeIt (DigitizeIt, Braunschweig, Ger-
many) was used, when possible, to extract the relevant data. When indi-
vidual patient data (IPD) were available, they were extracted preferentially
to summary data. The following study characteristics were extracted: au-
thor, year, journal/source, number of patients enrolled, study region, drug
dose, drug manufacturer, analytical method, and inclusion/exclusion cri-
teria. The following patient characteristics were extracted: age, sex,
weight, body mass index, serum creatinine concentration, and creatinine
clearance. The following outcomes were extracted: plasma drug concen-
tration according to time and summary parameters when no IPD were
provided, including oral clearance (CL), oral volume of distribution (V),
half-life, maximum concentration in plasma (Cmax), time to Cmax (Tmax),
absorption rate constant (Ka), elimination rate constant (kel), and the area
under the concentration-time curve (AUC).
Meta-analysis. Traditional meta-analysis uses summary data from
different studies, which are often obtained from publications, to estimate
the parameters of interest. In this meta-analysis, data from individual
patients were synthesized, resulting in a meta-analysis of the IPD. The
approach with IPD improves the quality of the data, the analyses, and,
subsequently, the reliability of the results. In addition, the information
from summary statistics was also integrated into an all-encompassing
meta-analysis. Given the complexity of the analysis, a Bayesian approach
was favored for its ability to deal with complex hierarchical models.
Analysis. Bayesian methods involve a formal combination of a prior
probability distribution (which reflects a prior belief of the possible values
FIG 1 PRISMA (preferred reporting items for systematic reviews and meta-
analyses) flow diagram of systematic literature search.
TABLE 1 Scope of review in terms of PIOS criteriaa
Criterion Scope of review
Population Healthy population and patients with Chagas disease
Intervention Benznidazole
Outcomes In adults receiving a single 100-mg dose of benznidazole, the
following outcomes were evaluated:
Cmax
Tmax
AUC0–t and AUC0–
CL/F
V/F
kel and elimination t1/2
Ka and absorption t1/2
Study design All trial types with PK evidence able to inform any of the
above-mentioned outcomes
a PIOS, population, interventions, outcomes, and study design; AUC0 –t, AUC from
time zero to time t; AUC0 –, AUC from time zero to infinity; t1/2, half-life.
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of the model parameters) with a (likelihood) distribution based on the
observed data to obtain a posterior probability distribution of the model
parameters (10). The likelihood informs us about the extent to which
different values for the parameter of interest are supported by the data. A
major advantage of the Bayesian approach is that the method naturally
leads to a decision framework (10–12) The posterior distribution can be
interpreted in terms of probabilities (e.g., there is an x percent probability
that treatment A results in a greater response than treatment B); frequen-
tist approaches do not allow such an interpretation (13).
The averaged likelihood is necessary in order for the posterior to be a
distribution. By definition, calculation of the averaged likelihood (and,
because of that, the posterior distribution) involves integration. This in-
tegration can become exorbitant, especially when the parameter of inter-
est is high dimensional. For years, the popularity of Bayesian statistics
suffered from the impracticable numerical integrations necessary to ob-
tain the posterior distribution. This changed after the introduction of
Markov chain Monte Carlo (MCMC) techniques, which resulted in a rise
in popularity of Bayesian statistics because it provides a tool to get around
the integration process. The most important and famous MCMC meth-
ods include the Gibbs sampler (14) and the Metropolis-Hasting algorithm
(15). The Gibbs sampler is based on the characteristic that the multivariate
distribution is uniquely determined by its conditional distributions and
was used throughout these analyses.
PK. PK is a well-established field in which many different models are
used to explain the absorption, distribution, and elimination of a drug
within the bloodstream. For this study, a single-compartment model with
the following core equation was used:
concentration 
F dose  Ka
V (Ka kel)
(ekel time  eKa time) (1)
where Ka is the absorption rate constant, kel is the elimination rate con-
stant, F is bioavailability, and V is the volume of distribution. It turns out
that all of the parameters of interest can be expressed as a function of three
parameters: Ka, CL, and V. V is the parameter that describes the tendency
of a drug to distribute out of the blood into the tissues. It represents the
volume of plasma necessary to account for all the drug in the body. The
elimination process is defined as the irreversible removal of drugs from
the body. The elimination mechanism is best described by the parameter
CL. Clearance is the theoretical volume of blood which is effectively
cleared of drug per unit of time. The formulas for the remaining param-
eters are as follows:
kel 
CL
V
(2)
AUC 
F dose  Ka
V (Ka kel)  kel
(3)
Tmax 
1
(Ka kel)
lnKakel (4)
Cmax 
F dose  Ka
V (Ka kel)
(ekel Tmax  eKa Tmax) (5)
ta,1⁄2 
ln(2)
Ka
(6)
tel,1⁄2 
ln(2)
kel
(7)
where ta,1/2 and tel,1/2 are the absorption and elimination half-lives, re-
spectively.
Thus, we used the PK model described in equation 1 as the basis for the
hierarchical model and derived the parameters in equations 2 to 7 from
the model parameters.
Hierarchical modeling. To discuss the modeling, let yijk be the kth
observation from the ith individual from the jth study with the corre-
sponding time tijk. The 3 by 1 vector of pharmacokinetic parameters for
individual i in the jth study is given by ij. The first stage of the model was
specified as
p(yijkij, )  N(fijk, 
1vijk) (8)
where fijk is the pharmacokinetic model evaluated at time tijk with the
individual PK parameters, equal to ij, vijk is the residual error structure, p
is the probability function, N is the normal distribution, and  is the
between-patient heterogeneity.
The second stage of the model was to model at the study level and was
specified as
p(iji, 	)  MVN(i, 	) (9)
where MVN( · ) represents a multivariate normal distribution, i (3 by 1)
represents the mean kinetic behavior of the ith individual, and (3 by 3)
is the corresponding variance-covariance matrix representing the within-
study variance.
The third stage of the hierarchical model represents the population
FIG 2 Study-level Forest plot for AUC (in milligram · hours per liter, as indicated on the x axis). The midline of each estimate (row) represents the point estimate
for the individual study (light blue) and the pooled estimate (dark blue). Each estimate extends to include the lower (left) and upper (right) bounds of the 95%
credible interval. The small arrow at the end indicates that the credible interval extends slightly beyond the scale of the x axis. Bronn, Lucano, and Raaflaub, the
studies of Bronn (17), Pergrina Lucano (20), and Raaflaub and Ziegler (22), respectively.
FIG 3 Study-level Forest plot for Cmax (in milligrams per liter, as indicated on the x axis). The midline of each estimate (row) represents the point estimate for
the individual study (light blue) and the pooled estimate (dark blue). Each estimate extends to include the lower (left) and upper (right) bounds of the 95%
credible interval.
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parameter estimation and was defined by making the following distribu-
tional assumptions:
p(i
, )  MVN(
, ) (10)
where 	 (3 by 1) is the mean value of the individual mean parameter
vector i, and
 (3 by 3) is the corresponding variance-covariance matrix
representing the between-study variance.
The definition of the hierarchical model is completed by the specifica-
tion of the fourth stage, in which prior densities are assigned to the pa-
rameters. In particular, the variance-covariance matrices are defined us-
ing a Wishart prior distribution, the population PK parameters are given
a multivariate normal prior distribution, and the residual variance factor
is defined using an inverse uniform distribution.
In addition to using a hierarchical model to account for the within-
individual and study correlation, the model also used an adjustment for
whether patients had had food or were fasting. This was accomplished by
having a regression adjustment on the absorption rate parameter, such
that Ka was replaced by (Ka  x), where x is a metaregression adjust-
ment term used to account for whether a patient is fasting or not, through-
out equation 1. It was judged that food but not the volume of distribution
or clearance would affect absorption.
In order to integrate the summary statistics from four studies, the
information was used to create empirical priors for clearance and volume.
In this way, the analysis included a 5th stage by which the information
from summary statistics was first integrated and then updated using the
four hierarchical stages described above.
The data were analyzed in R (version 3.2.1). The Bayesian analyses
were performed using an MCMC method implemented in the JAGS (ver-
sion 3.4.0) software package (16). A first series of 60,000 iterations from
the JAGS sampler was discarded as burn-in, and the inference was based
on an additional 100,000 iterations using two chains.
RESULTS
Evidence base. A total of 462 citations were identified through the
database search and through a hand search of the literature (Fig.
1). Of these, 441 were excluded at the abstract screening stage. This
resulted in the screening of the full text of the articles describing 21
studies. Of these, 12 were excluded: 1 because of an ineligible study
design, 7 because the populations studied did not inform the pri-
mary analysis of interest (i.e., a single-dose pharmacokinetic anal-
ysis), 2 because the intervention of interest was not included, and
2 because the outcome of interest was not included. This resulted
in a total of 9 studies that were included in the analysis (17–25).
There were no single-dose PK studies of benznidazole in children.
The final list of studies included in the analysis is presented in
Table 2.
The nine studies included were published or released between
1979 and 2016. One of these studies was a secondary publication
of data contained in a prior study, and therefore, the data from
that study were not included separately in the final data extraction
sheets (23). Three studies contained individual patient-level data
from studies of a single benznidazole dose of 100 mg (17, 20, 22).
One was a published study (22); one was an unpublished trial
report (17); and one was a Ph.D. thesis (20), which also remained
unpublished and was obtained from the corresponding university
archives with authorization for the purpose of this analysis. Three
studies contained limited individual patient-level data from mul-
tidose studies (18, 20, 21). Of these, only the study by Raaflaub
(21) provided data pertinent to the primary analyses. One addi-
tional study contained some further single-dose summary data.
This was a study of a single dose of 25 mg/kg in oncology patients
(24). A further two studies evaluated benznidazole, using typical
therapeutic doses, in a sample of patients with Chagas disease.
These studies provided some summary kinetic parameters that
were available for incorporation as priors into the final PK model
(19, 25).
Pharmacokinetic parameters. Nine pharmacokinetic param-
eters were estimated at the individual level and study level and as
an overall estimate that included the use of empirical priors, when
available. The study-level and overall adjusted data along with
95% credible intervals are presented in Table 3. The study-level
and overall adjusted data along with 90% credible intervals (CrIs)
are presented in appendix B in the supplemental material.
Area under the curve. The overall AUC for the final 100-mg-
dose model, including all the available data, was 51.31 mg · h/liter
(95% CrI, 45.01, 60.28 mg · h/liter). Only three studies informed
this parameter (17, 20, 22). The consistency between studies was
excellent, with little heterogeneity from visual assessment of the
Forest plot (Fig. 2). The Forest plot with the corresponding 90%
credible intervals is shown in appendix B in the supplemental
FIG 4 Study-level Forest plot for Tmax (in hours, as indicated on the x axis). The midline of each estimate (row) represents the point estimate for the individual
study (light blue) and the pooled estimate (dark blue). Each estimate extends to include the lower (left) and upper (right) bounds of the 95% credible interval.
FIG 5 Study-level Forest plot for kel (in hours
1, as indicated on the x axis). The midline of each estimate (row) represents the point estimate for the individual
study (light blue) and the pooled estimate (dark blue). Each estimate extends to include the lower (left) and upper (right) bounds of the 95% credible interval.
The small arrow at the end indicates that the credible interval extends slightly beyond the scale of the x axis.
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material. All 90% credible intervals of the individual studies fell
within 80% and 125% of the overall estimate, suggesting accept-
able heterogeneity. The study presented in the thesis by Peregrina
Lucano (20) deviated the most from the overall parameter esti-
mate, but it deviated by only approximately 6%.
Maximum plasma concentration. The overall Cmax for the
final 100-mg-dose model with all the available data was 2.19 mg/
liter (95% CrI, 2.06, 2.33 mg/liter). The same three studies that
informed the AUC informed this parameter (17, 20, 22). Although
the variability in Cmax between studies was higher than that for
AUC, the 90% and the 95% credible limits of each of the individ-
ual studies remained between 80% and 125% of the overall esti-
mate. Figure 3 shows the Forest plot for Cmax, and it can be ob-
served that heterogeneity was minimal, with the point estimates
being contained in all the credible intervals.
Time to maximum plasma concentration. The overall calcu-
lated Tmax was 2.93 h (95% CrI, 2.57, 3.48 h). As with AUC and
Cmax, only the three primary studies informed the analysis of this
parameter (17, 20, 22). Tmax was more heterogeneous between
studies than either AUC or Cmax, but overall, the variability was
consistent with the degree of variability seen within studies (Fig.
4). The variability in Tmax was primarily associated with the ab-
sorption rate constant (Ka), which in turn was affected by a variety
of factors, including the formulation administered and patient
factors, such as gastric emptying and, potentially, food effects.
Given a constant elimination rate constant, as Ka decreases, Tmax
increases. Since Ka is inherently more variable and difficult to
measure, there is likely to be a higher degree of variability in pa-
rameters such as Tmax than in Cmax or AUC.
Elimination rate constant. The elimination rate constant uti-
lized the patient-level data from the three primary studies (17, 20,
22) but was further informed by two additional studies that pro-
vided summary (study-level) data that could be incorporated into
the Bayesian model as empirical priors (21, 24). The overall elim-
ination rate constant was 0.052 h1 (95% CrI, 0.045, 0.059 h1).
The study-level data from the three primary studies (17, 20, 22)
were very consistent with the overall estimates, as visually depicted
in Fig. 5. The final estimate of the elimination half-life was 13.27 h
(95% CrI, 11.79, 15.42 h).
Absorption rate constant. The absorption rate constant was
the parameter with a high degree of both within-study and be-
tween-study heterogeneity (Fig. 6; see also appendix B in the sup-
plemental material). This was reflected in the wide credible inter-
vals in the study-level and overall estimates. The overall estimate
was 1.16 h1 (95% CrI, 0.59, 1.76 h1), with a resulting absorption
half-life of 0.60 h (95% CrI, 0.38, 1.11 h). The data from the study
presented in the thesis by Peregrina Lucano (20) differed the most
from the data from the two other studies.
Apparent volume of distribution. The apparent volume of
distribution (V/F) was estimated, and the overall results were re-
markably consistent with the estimated results (Fig. 7). Although
summary data from two additional studies (19, 25) were used to
derive an empirical prior, the results remained consistent. The
overall V/F was 39.19 liters (95% CrI, 36.58, 42.17 liters).
Apparent oral clearance. The apparent oral clearance was also
estimated utilizing empirical priors for two studies (19, 25). The
overall clearance (CL/F) was estimated to be 2.04 liters/h (95%
CrI, 1.77, 2.32 liters/h), fitting in well with the results from the
three primary studies (17, 20, 22), in which the apparent oral
clearances ranged from 1.95 to 2.10 liters/h. Figure 8 shows the
study-level Forest plot for clearance, with the results being consis-
tent with each other and the overall estimate.
DISCUSSION
This is the first meta-analysis of pharmacokinetic studies of ben-
znidazole. Using a Bayesian meta-analytic framework, all pharma-
cokinetic data relevant to the parameters of interest from PK stud-
ies of a single benznidazole dose of 100 mg in adults were utilized,
thereby producing estimates better than those that could other-
wise be derived using a typical frequentist framework. The pri-
mary oral PK parameters of interest, including AUC, Cmax, Tmax,
kel, V/F, and CL/F, showed remarkable consistency between the
three primary studies providing patient-level data (17, 20, 22).
Although at the individual level there was significant heterogene-
ity (i.e., within-study heterogeneity), the between-study heteroge-
neity was modest, suggesting that each study was estimating the
population parameter reasonably well and further suggesting that
the use of the meta-analytic technique to combine data is well
FIG 6 Study-level Forest plot for Ka (in hours
1, as indicated on the x axis). The midline of each estimate (row) represents the point estimate for the individual
study (light blue) and the pooled estimate (dark blue). Each estimate extends to include the lower (left) and upper (right) bounds of the 95% credible interval.
FIG 7 Study-level Forest plot for V/F (in liters, as indicated on the x axis). The midline of each estimate (row) represents the point estimate for the individual
study (light blue) and the pooled estimate (dark blue). Each estimate extends to include the lower (left) and upper (right) bounds of the 95% credible interval.
The small arrows at the ends of the estimates indicate that the credible interval extends slightly beyond the scale of the x axis.
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justified. When available, additional data from multidose studies
and other single-dose studies were used to provide empirical pri-
ors to further strengthen the final parameter estimates. These data
did not substantially change any parameter estimates, further
strengthening the reliability of these results.
An important consideration in meta-analysis is between-study
heterogeneity. The degree to which heterogeneity influences the
interpretation of results is often subjective and has been widely
debated (26). Because few meta-analyses of PK studies have been
conducted, the interpretation of between-study heterogeneity is
even less well established. As the primary objective of this meta-
analysis was to improve the estimates of the oral PK parameters
derived from single-dose studies, it must be the case that the stud-
ies included in the meta-analysis may actually be sufficiently sim-
ilar to be combinable. The acceptance criteria for bioequivalence
by the Food and Drug Administration is that the 90% confidence
intervals of the mean AUC and Cmax for the test formulation be
within 80% and 125% of the values for the reference formulation
(27). By taking the reference formulation as the combined esti-
mate and the test formulations as the individual studies, the bio-
availability criteria would be met with both AUC and Cmax. Fur-
thermore, heterogeneity, as visually assessed with the Forest plots,
showed consistency between the three primary studies (17, 20, 22)
for these outcomes, as well as the other pharmacokinetic param-
eters.
This study is subject to several limitations. First, this study
began with the assumption of a one-compartment model with
first-order elimination. While not a limitation per se, it assumed
that prior studies of the pharmacokinetics of benznidazole per-
formed to determine its basic kinetic properties were correct. A
careful examination of the individual-level data presented in ap-
pendix C in the supplemental material, however, confirms that the
model reflects the data well. Second, although a major advantage
of this meta-analysis was the use of patient-level data, these data
were collected over a period of more than 30 years from various
populations in which a variety of formulations and for which dif-
ferent analytic techniques for drug quantification in plasma were
used. However, the consistency of our results, despite these fac-
tors, further strengthens the possibility that subsequent studies on
the pharmacokinetic characteristics of benznidazole would pro-
duce similar parameter estimates.
The treatment of Chagas disease, a paradigmatic case of a ne-
glected tropical disease, suffers from the lack of resources at both
the research and implementation levels; therefore, new develop-
ments are scarce, and there are plenty of unsolved aspects of the
currently available treatments. In view of these limitations, efforts
to find solutions to some of these uncertainties through innova-
tive validated analytic methods like this meta-analysis help in the
process of the acquisition of knowledge about drugs like ben-
znidazole, around which clear clinical benefits have been observed
in certain situations, like acute infections and vertical transmis-
sion, but not in others (28).
While this meta-analysis addresses the single-dose pharmaco-
kinetics of benznidazole in adults, these methods could also be
applied to both existing pediatric data and multidose data. The
advantage of our Bayesian approach was its incorporation of em-
pirical priors into the final analysis. Using this approach, multi-
dose IPD, such as those presented by Raaflaub (21), along with
data from other population-based PK studies, could be analyzed.
Furthermore, utilizing the single-dose data derived in this meta-
analysis, models could be further improved by the incorporation
of relevant PK parameters not derived from multidose studies.
In conclusion, this meta-analysis of pharmacokinetic studies
has provided improved estimates of the pharmacokinetic param-
eters under fasting conditions for a single 100-mg dose of ben-
znidazole in adults. The overall results reflect the individual stud-
ies from which they were derived. These summary parameters can
be used by clinicians and policy makers as the treatment of Chagas
disease is scaled up throughout Latin America.
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